SOURCE: INVO Bioscience, Inc.

January 06, 2010 20:34 ET

INVO Bioscience, Inc. Announces Registration Statement Effective

BEVERLY, MA--(Marketwire - January 6, 2010) - INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today that the SEC declared its Registration Statement on Form S-1 filed on December 21, 2009 effective on December 30, 2009. The Registration Statement becoming effective will satisfy one of the primary conditions in allowing INVO Bioscience to sell securities from time to time to AGS Capital Group, LLC to obtain funding as outlined in the Registration Statement and the 8-K filed November 3, 2009. The Company has submitted an Advance Request this week and anticipates funds from the request on January 8, 2010. "INVO Bioscience now has satisfied the primary condition for our ability to obtain the needed funds to expand sales and execute the business plan," stated Katie Karloff, INVO Bioscience's CEO.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. Factors that may limit our ability to sell shares to AGS Capital Group, LLC are included in the Registration Statement on Form S-1 filed on December 21, 2009 and amended on December 28, 2009. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Contact:
    Kathleen Karloff
    INVO Bioscience, Inc.
    978-878-9505 extension 508
    Email Contact